Phase 4
N=30
Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
Blepharitis
Bottom Line
View on ClinicalTrials.gov: NCT01478256 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Nov 2013
Primary outcome: Primary: Improvement in Signs and Symptoms of Blepharitis — 15; 15 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Erythromycin (Drug); Besifloxocin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- John, George, M.D.
- Primary completion
- Oct 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Improvement in Signs and Symptoms of Blepharitis |
15; 15 | — |
| SECONDARY Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics |
15; 15 | — |
Summary
This study looks at the improvements in signs and symptoms in patients with inflammation of the lids, blepharitis, using two different FDA approved topical antibiotic agents, Besifloxocin and Erythromycin. It also evaluates the bacterial cultures in these patients for microbiologic evidence of improvement.
Eligibility Criteria
Inclusion Criteria:Acute blepharitis, age 18-100, Signs and symptoms of blepharitis -
Exclusion Criteria: women of child bearing potential, eye surgery within three months of study, contact lens wear, use of topical or antibacterial agents in past two weeks, use of topical or oral steroids in past two weeks unless stable dosage
-
Data sourced from ClinicalTrials.gov (NCT01478256). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.